Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
mldpfdd.org/ Op 21 oktober was er een meting waarbij o.a. FDA rechtstreeks in gesprek konden gaan met patiënten Hoopvol dat er voor eind 2022 nog nieuws komt vanuit de FDA In november (18e) staat er nog iets op de agenda. Cheers
Ben 'blij' te lezen dat het jullie ook enigszins heeft verbaasd. Bedankt voor jullie input...
Ik mag dan wel staar hebben maar niet kleurenblind. Groen...... Succes alle positivo's.
Jinxter schreef op 23 oktober 2022 20:31 :
mldpfdd.org/ Op 21 oktober was er een meting waarbij o.a. FDA rechtstreeks in gesprek konden gaan met patiënten
Hoopvol dat er voor eind 2022 nog nieuws komt vanuit de FDA
In november (18e) staat er nog iets op de agenda.
Cheers
Even weer tijd voor kleine positieve berichtgeving, zie onderstaand. seekingalpha.com/article/4550783-phar... Joseph Pantginis Got it. And then just lastly, and this is really the part I alluded to where your hands might be tied with regard to how you answer it. So with 105, obviously, there's a bit of growing excitement for potential gene therapy around HAE, and this certainly came out at the recent HAE conference that we hosted. So I was just wondering, right now if you'll give us information as it comes out. Is there anything that we could look to even without timing that as the plan would be to release X type of preclinical data to be able to tease the profile of the asset? Anurag Relan So Joe, that's really the goal here, right? So I think, first of all, what got us into this position or why did we enter this partnership with Orchard was that we believe, again, around C1 inhibitor. We believe C1 inhibitor is the root cause of -- we know it's the root cause in these patients and we wanted to be able to provide these patients with C1 inhibitor in the same way that we do with RUCONEST to be able to do that with a gene therapy. The other modalities that we looked at really didn't present themselves with a reliable way to do that. So the goal now in terms of these preclinical models is to be able to use a vector that now has been refined by the team at Orchard and to be able to show that we can actually increase the C1 inhibitor levels in these disease models. So these are disease models being knocked out mice that have -- that don't have the C1 inhibitor gene in place. And now can you increase those levels to levels that we think would be meaningful in a clinical situation. And we're doing that testing now. So I'm hopeful to be able to provide an update on that soon. But those are the -- that's the type of information that we can look for is, say, can we show meaningful increases in C1 inhibitor expression levels in these preclinical disease models that could translate into the type of benefit that we would need to see in patients. Zoals ik al vermoedde, bestaan de preclinical desease models, uit onder narcose gebrachte muisjes, die niet over het C1inh gen beschikken. De vector waaraan gerefereerd wordt, lijkt aan kwaliteit te verbeteren, en Orchard heeft hiervoor een partnership gesloten met Oxford Biomedica, ook al staat het niet als zodanig op de website van Orchard, hetgeen mij enigszins bevreemdt, e doch lijkt het zijn vruchten af te werpen: www.oxb.com/news-media/press-release/... As part of the project, Oxford Biomedica’s LentiStable™ technology platform will be used to develop a producer cell line capable of stably expressing lentiviral vectors. De koers blijft waarachtig te stabiliseren op 0.45. De kosten voor dit aandeel lijkt 0.017 te zijn, en de custodian lijkt voorlopig de lachende derde te zijn. Salut
Volgens mij worden donderdag de 3e kwartaalcijfers bekend gemaakt..? Kunnen we nog geks verwachten of kabbelen we rustig richting eind 2022, waarin we nog wat meer nieuws mogen gaan verwachten..? Groet, Mr. 3L
Press Releases Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022 Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST BOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced early clinical findings from its ongoing proof-of-concept study of investigational OTL-201 in MPS-IIIA will be featured in an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 10-13, 2022, in New Orleans. The oral presentation at ASH 2022 will showcase the first neurocognitive data for all patients and extend upon previously presented biochemical results, with a median follow-up of 1.5 years. The presentation details are listed below. Abstracts are available on the ASH website. Title: “Biochemical Engraftment and Clinical Outcomes Following Ex-Vivo Autologous Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIA” Date/Time: Monday, December 12, 2022, at 10:45 a.m. CST Presenter: Professor Rob Wynn, consultant pediatric hematologist and director of Pediatric Bone Marrow Transplant Program, Royal Manchester Children’s Hospital (RMCH), part of Manchester University NHS Foundation Trust Room: Ernest N. Morial Convention Center, 220-222 Orchard is planning to host a virtual KOL investor webcast on Monday, December 12, 2022, at 5:00 p.m. EST to review the data presented at the meeting. A live webcast will be available under “Events” in the Investors & Media section of the company’s website at www.orchard-tx.com and a replay of the webcast will be archived following the event. Five patients with MPS-IIIA, aged 6 to 24 months, were treated with OTL-201 as part of this ongoing proof-of-concept trial, sponsored by The University of Manchester, conducted at Royal Manchester Children’s Hospital, and funded by Orchard Therapeutics. Primary study objectives include safety, tolerability and peripheral expression of SGSH activity in total leukocytes at 12 months. Secondary study objectives include overall survival and neurocognition as measured by the Bayley Scales of Infant and Toddler Development. Patients will be followed for a minimum of three years. About MPS-IIIA Mucopolysaccharidosis type IIIA (MPS-IIIA, also known as Sanfilippo syndrome type A) is a rare and life-threatening metabolic disease. People with MPS-IIIA are born with a mutation in the N-sulphoglucosamine sulphohydrolase (SGSH) gene which, when healthy, helps the body break down sugar molecules called mucopolysaccharides. The buildup of mucopolysaccharides in the brain and other tissues leads to intellectual disability and loss of motor function. MPS-IIIA occurs in approximately one in every 100,000 live births. Life expectancy of children born with MPS-IIIA is estimated to be between 10-25 years. About OTL-201 OTL-201 is an investigational hematopoietic stem cell gene therapy being developed for the treatment of MPS-IIIA. It uses a modified virus to insert a functional copy of the SGSH gene into a patient’s hematopoietic stem cells. OTL-201 has received rare pediatric disease designation from the FDA and is currently being evaluated in an ongoing proof-of-concept clinical trial. About Orchard Therapeutics At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment. In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard is advancing a pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com , and follow us on Twitter and LinkedIn. About Manchester University NHS Foundation Trust (MFT) Manchester University NHS Foundation Trust (MFT) is the largest NHS trust in England and a leading provider of specialist healthcare services. Its 10 hospitals are home to hundreds of world class clinicians and academic staff, committed to finding patients the best care and treatments. Its hospitals are Manchester Royal Infirmary, Saint Mary's Hospital, Royal Manchester Children's Hospital, Manchester Royal Eye Hospital, North Manchester General Hospital, University Dental Hospital of Manchester, Trafford General Hospital, Altrincham Hospital, Wythenshawe Hospital and Withington Hospital. More information is available at: www.mft.nhs.uk. About The University of Manchester The University of Manchester is a member of the prestigious Russell Group and one of the UK’s largest single-site universities. We have over 40,000 students, 12,000 staff and, with almost 480,000 former students from more than 190 countries, are home to the largest alumni community of any campus-based university in the UK. We are ranked in the top ten of the Times Higher Education (THE) Impact Rankings globally; are the top UK University for graduate employability according to The Graduate Market in 2022 and no fewer than 25 Nobel laureates have either worked or studied here. Visit www.manchester.ac.uk for further information or www.manchester.ac.uk/discover/vision/ for our latest strategic vision.
(vervolg) Availability of Other Information About Orchard Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchard’s investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Forward-looking Statements This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchard’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchard’s most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission (SEC), as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchard’s views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Contacts Investors Renee Leck Senior Director, Investor Relations +1 862-242-0764 Renee.Leck@orchard-tx.com Media Benjamin Navon Director, Corporate Communications +1 857-248-9454 Benjamin.Navon@orchard-tx.com Bron: ir.orchard-tx.com/news-releases/news-...
@ Mr.3L, Passenger, Iris, Mooi vooruitzicht richting de kerstdagen en het nieuwe jaar (2023). Cheers to a great future in gen-technologie!
Jinxter schreef op 3 november 2022 16:14 :
@ Mr.3L, Passenger, Iris,
Mooi vooruitzicht richting de kerstdagen en het nieuwe jaar (2023).
Cheers to a great future in gen-technologie!
Nu maar eerst even kennis nemen van de Q3-cijfers. Ik vind ze wel laat vergeleken met voorgaande kwartalen, altijd 1e week van de nieuwe maand volgend op het kwartaal. Ik verwacht overigens dat het aantal behandelingen tegen MLD niet significant is gestegen. Verder hoop ik te horen of de reimbursement een keertje er doorheen is met Spanje, Benelux en Frankrijk. Pffff, dat blijft ook maar voortduren, terwijl de kinderen wel verder blijvend kunnen worden beschadigd door deze ziekte. Desalniettemin… ir.orchard-tx.com/news-releases/news-... 14 Nov cijfers, 18 Nov 2e call, over MLD in de USA. Salut
Orchard Therapeutics Q3 2022 Inkomstenvoorbeeld 11 november 2022 12:17 ET Orchard Therapeutics plc (ORTX) Door: Manshi Mamtora , CFA Orchard Therapeutics ( NASDAQ: ORTX ) zal naar verwachting op vrijdag 11 november, na sluiting van de markt, de resultaten over het derde kwartaal bekendmaken. De consensus EPS-schatting is -$ 0,22 en de consensus-inkomstenschatting is $ 4,41 miljoen (+270,6% J/J). In de afgelopen 3 maanden zijn de WPA-ramingen 1 naar boven bijgesteld en 2 naar beneden bijgesteld. Inkomstenramingen hebben 3 opwaartse herzieningen en 0 neerwaartse bijstellingen gezien.
Morgen de 14e voorbeurs nieuws vanuit Orchard Therapeutics. Zou de 14 morgen iets speciaals hebben? In de USA las ik een artikel op een forum wat positief was over een onderzoek.ash.confex.com/ash/2022/webprogram/Pa... Cheers to gen technologie
Knap hoor om deze gegevens op te sporen , dankjewel
Orchard Therapeutics GAAP EPS of -$0.37 misses by $0.13, revenue of $5.78M beats by $1.37M Nov. 14, 2022 7:04 AM ETOrchard Therapeutics plc (ORTX)By: Meghavi Singh, SA News Editor Orchard Therapeutics press release (NASDAQ:ORTX): Q3 GAAP EPS of -$0.37 misses by $0.13. Revenue of $5.78M (+385.7% Y/Y) beats by $1.37M. Cash, cash equivalents and investments as of September 30, 2022, were $146.6M, with $33.0M of debt outstanding, compared to $220.1M and the same debt figure as of December 31, 2021. The company expects that its existing cash, cash equivalents and investments will now fund its anticipated operating, debt service and capital expenditure requirements into the second quarter of 2024.
Orchard Therapeutics GAAP WPA van -$ 0,37 mist $ 0,13, omzet van $ 5,78 miljoen verslaat $ 1,37 miljoen 14 november 2022 07:04 ET Orchard Therapeutics plc (ORTX) Door: Meghavi Singh , SA Nieuwsredacteur Persbericht Orchard Therapeutics ( NASDAQ: ORTX ): Q3 GAAP WPA van -$0,37 mist $0,13 . De omzet van $ 5,78 miljoen (+385,7% op jaarbasis) overtreft $ 1,37 miljoen . Geldmiddelen, kasequivalenten en investeringen per 30 september 2022 bedroegen $ 146,6 miljoen, met een uitstaande schuld van $ 33,0 miljoen, vergeleken met $ 220,1 miljoen en hetzelfde schuldcijfer op 31 december 2021. Het bedrijf verwacht dat de bestaande geldmiddelen, kasequivalenten en investeringen nu in het tweede kwartaal van 2024 de verwachte operationele, schuldendienst en kapitaaluitgaven zullen financieren.
nl.investing.com/news/orchard-winst-l... Investing.com - Orchard rapporteerde op maandag voor het derde kwartaal een winst die lager is dan verwacht en een omzet die hoger is dan de voorspellingen. Het bedrijf meldt een winst per aandeel van $-0,370 met een omzet van $5,78M. Analisten geraadpleegd door Investing.com voorzagen een winst per aandeel van $-0,230 met een omzet van $4,41M. Dit jaar zijn Orchard aandelen vooralsnog 3.5% hoger uitgekomen, waardoor ze beter presteren dan de Nasdaq die 27% lager is uitgekomen in het lopende jaar. Orchard in reeks belangrijke aandelen in de gezondheidszorgsector deze maand Op 18 oktober rapporteerde J&J voor het derde kwartaal een winst per aandeel van $2,55 bij een omzet van $23,79B, in vergelijking met een voorspelde winst van $2,48 en een omzet van $23,36B. Eli Lilly rapporteert op 1 november voor het derde kwartaal een winst die hoger is dan verwacht, namelijk een winst per aandeel van $1,98 bij een omzet van $6,94B. Investing.com analisten verwachtten een winst van $1,91 en een omzet van $6,91B
Met dank aan poster Holmes:holmes schreef op 15 november 2022 09:17 :
Uit:
Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights
Research programs:
Report preclinical POC data for the OTL-104 program in NOD2 Crohn’s disease in early 2023 in advance of IND-enabling studies and an IND submission in 2024.
Continue to advance the OTL-105 program in hereditary angioedema (HAE), OTL-204 program for GRN-FTD and work in HSC-generated antigen-specific Tregs.
Collaboration revenue was $0.4 million for the three months ended September 30, 2022, resulting from the collaboration of OTL-105 in HAE with Pharming Group N.V. entered into in July 2021. This revenue represents reimbursements for research costs and preclinical studies incurred by the company and a portion of the $17.5 million upfront consideration received by Orchard under the collaboration, which is being amortized into revenue over the expected duration of the agreement.
Net loss was $47.6 million for the three months ended September 30, 2022, compared to $36.4 million in the same period in 2021. The company had approximately 128.1 million ordinary shares outstanding as of September 30, 2022.
ir.orchard-tx.com/news-releases/news-...
Het is stil hier, allemaal fingers crossed? We hebben gisteren toch nog wat bijgekocht, klein beetje maar hoor. :-) Wie niet wa.....
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)